论文部分内容阅读
作者按1965年MRC标准选择285名具有代表性的中度慢性支气管炎患者进行多中心双盲法试验。在开始试验之前一个月停用化痰、镇咳和解痉剂,并以单盲法给予安慰剂。随后,随机将患者分为2组:一组口服乙酰半胱氨酸200mg Bid,另一组给安慰剂Bid,均用双盲法,于冬季发病率最高时开始试验,疗程6个月。患者每周2次在随访卡上填写有关症状。在疗程的第2、4、6月由专人随访病人并参照1976年FIetcher等的标准从记录卡上分析发作次数,判断疗效。共203人按计划完成试验,口服乙酰半胱氨酸组98人,安慰剂组105人。两组间在年龄、病程、吸烟人数和上1年急性发作次数之间无显著差异。试验期间的急性发作频率,口服乙酰半胱氨酸组为127人次,显著低于安慰剂组的215人次(P<0.01)。急性发作
The authors selected 285 patients with moderate-grade chronic bronchitis under the 1965 MRC standard for a multicenter, double-blind trial. Phlegm, antitussive and antispasmodic agents were discontinued one month prior to the start of the trial and placebo was given in a single blinded fashion. Subsequently, the patients were randomized into two groups: one group with 200 mg bid of acetylcysteine, and the other with placebo Bid, both of which were double-blinded and started testing at the highest winter incidence for 6 months. Patients fill in the relevant card twice a week on the card. Patients were followed up by hand during the 2nd, 4th, and 6th month of the course of treatment, and the number of seizures was analyzed from the record card with reference to FIetcher et al. In 1976 to determine the efficacy. A total of 203 people completed the trial as planned, with 98 subjects in the oral acetylcysteine group and 105 in the placebo group. There was no significant difference between the two groups in terms of age, duration of disease, number of smokers and number of acute attacks in the previous year. The frequency of acute attacks during the trial was 127 for the oral acetylcysteine group, which was significantly lower than 215 for the placebo group (P <0.01). Acute attack